Document is current
Any future updates will be listed below
-
Authors
Fountzilas, Elena https://orcid.org/0000-0002-4884-2544
Pearce, Tillman
Baysal, Mehmet A. https://orcid.org/0000-0002-8446-6531
Chakraborty, Abhijit https://orcid.org/0000-0002-3822-5657
Tsimberidou, Apostolia M. https://orcid.org/0000-0003-2713-233X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Clinical Center (P30 CA016672)
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 19 January 2025
First Online: 31 January 2025
Competing interests
: A.M.T. declares receipt of Clinical Trial Research Funding (received through the institution): OBI Pharma, Agenus, Vividion, Macrogenics, AbbVie, IMMATICS, Novocure, Tachyon, Parker Institute for Cancer Immunotherapy, Tempus, and Tvardi; fees for consulting or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I, and VinceRx. E.F. declares advisory role of Amgen LEO Pharma; travel grants from Merck, Pfizer, AstraZeneca, DEMO and K.A.M. Oncology/Hematology; Speaker fees from Roche, Leo, Pfizer, AstraZeneca, Amgen; and Stock ownership from Genprex Inc., Deciphera Pharmaceuticals, Inc. The remaining authors declare no relevant conflict of interest.
